Public trial registry of the CCC-Munich

Trial AGO-OVAR 12 / LUME-Ovar 1

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AGO-OVAR 12 / LUME-Ovar 1
World
Full title
:

Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

World
Description
:

The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
KUM - GYN - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe (Großhadern) Lmu
Indications
Classification Code Description
ICD-10-GM C56 Bösartige Neubildung des Ovars
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Double blinded
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
BfArM - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.